{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:33:13Z","timestamp":1792290793074,"version":"4.4.0"},"reference-count":12,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2013,10]]},"abstract":"Summary<\/jats:title>\n \n Objective<\/jats:title>\n \n Denosumab is a new potent antiresorptive treatment of osteoporosis that can potentially induce a compensatory increase in parathyroid hormone (\n PTH<\/jats:styled-content>\n ) levels. We aimed to evaluate the alteration of\n PTH<\/jats:styled-content>\n 1 and 6\u00a0months after denosumab's administration with different regimens of calcium and vitamin D (Ca\/D) supplementation.\n <\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Prospective, multicenter, study in a relatively small, heterogeneous sample of postmenopausal women followed for 6\u00a0months.<\/jats:p>\n <\/jats:sec>\n \n Patients<\/jats:title>\n \n Forty seven postmenopausal women followed in 2 outpatient clinics, requiring onset or continuation of osteoporosis treatment. We administered 1\u00a0g calcium carbonate and 800\n IU<\/jats:styled-content>\n cholecalciferol daily for 6 months (Group A) or the double dose for the first month followed by the 1\u00a0g\/800\n IU<\/jats:styled-content>\n Ca\/D regimen for the next 5 months (Group B).\n <\/jats:p>\n <\/jats:sec>\n \n Measurements<\/jats:title>\n \n Parathyroid hormone (\n PTH<\/jats:styled-content>\n ) alterations between and within groups, and their associations with serum Ca and bone markers.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Parathyroid hormone (\n PTH<\/jats:styled-content>\n ) levels were significantly higher at month 1 and 6 only in Group A; Ca levels were significantly decreased at month 1 and returned to baseline values at month 6 within the same Group. The mean per cent change between month 1 and baseline for\n PTH<\/jats:styled-content>\n [\u0394(\n PTH<\/jats:styled-content>\n 1\u20100<\/jats:sub>\n )] was significantly higher in Group A than B (63\u00b75%\u00a0\u00b1\u00a028\u00b72%\n vs<\/jats:italic>\n \u22123\u00b70%\u00a0\u00b1\u00a04\u00b77%,\n P<\/jats:italic>\n \u00a0=\u00a00\u00b7029). \u0394(\n PTH<\/jats:styled-content>\n 1\u20100<\/jats:sub>\n ) was correlated with the reciprocal \u0394\u2010changes of Ca (\n r<\/jats:italic>\n s\u00a0<\/jats:sub>\n =\u00a0\u22120\u00b7610;\n P<\/jats:italic>\n \u00a0=\u00a00\u00b7002) and collagen type I C\u2010terminal telopeptide (\n r<\/jats:italic>\n s\u00a0<\/jats:sub>\n =\u00a0\u22120\u00b7697;\n P<\/jats:italic>\n \u00a0=\u00a00\u00b7003) only in Group A.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n An increase in\n PTH<\/jats:styled-content>\n should be expected, at least following the first administration of denosumab in common clinical practice. The effect of this compensatory onsequence in bone metabolism warrants further investigation.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/cen.12188","type":"journal-article","created":{"date-parts":[[2013,3,2]],"date-time":"2013-03-02T12:13:29Z","timestamp":1362226409000},"page":"499-503","source":"Crossref","is-referenced-by-count":61,"title":["Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis"],"prefix":"10.1111","volume":"79","author":[{"given":"Polyzois","family":"Makras","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes 251 Hellenic Air Force & VA General Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[{"name":"Second Medical Clinic Ippokration Hospital Aristotle University of Thessaloniki Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Papatheodorou","sequence":"additional","affiliation":[{"name":"Department of Medical Research 251 Hellenic Air Force and VA General Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Kokkoris","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes 251 Hellenic Air Force & VA General Hospital Athens Greece"},{"name":"Department of Medical Research 251 Hellenic Air Force and VA General Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Chatzifotiadis","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine 251 Hellenic Air Force and VA General Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[{"name":"Department of Endocrinology 424 Military Hospital Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S24239"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.101964"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040305"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.81"},{"issue":"1","key":"e_1_2_7_7_1","first-page":"S1","article-title":"The Transitory increase in PTH Following Denosumab Administration is Associated with Reduced Intracortical Porosity: a Dinstictive Attribute of Denosumab Therapy","volume":"26","author":"Seeman E.","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1225"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.251"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1479"},{"issue":"1","key":"e_1_2_7_11_1","first-page":"S1","article-title":"The effects of combined Denosumab and Teriparatide administration on bone mineral density in postmenopausal women: the DATA (Denosumab And Teriparatide Administration) Study","volume":"27","author":"Leder B.","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.238"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d2040"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcen.12188","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.12188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:47:08Z","timestamp":1696340828000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.12188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/cen.12188"],"URL":"https:\/\/doi.org\/10.1111\/cen.12188","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718014194.793477375","asserted-by":"object"}]},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}